| Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer International Adjuvant Lung Cancer Trial Collaborative Group New England Journal of Medicine 350 (4), 351-360, 2004 | 3015 | 2004 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2515 | 2017 |
| DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2347 | 2006 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, JR Pereira, A Szczesna, J von Pawel, M Krzakowski, R Ramlau, ... The Lancet 373 (9674), 1525-1531, 2009 | 1819 | 2009 |
| Expression of multidrug resistance gene in human cancers LJ Goldstein, H Galski, A Fojo, M Willingham, SL Lai, A Gazdar, R Pirker, ... JNCI: Journal of the National Cancer Institute 81 (2), 116-124, 1989 | 1742 | 1989 |
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 … R Pirker, JR Pereira, J Von Pawel, M Krzakowski, R Ramlau, K Park, ... The lancet oncology 13 (1), 33-42, 2012 | 688 | 2012 |
| Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Vansteenkiste, R Pirker, B Massuti, F Barata, A Font, M Fiegl, S Siena, ... Journal of the National Cancer Institute 94 (16), 1211-1220, 2002 | 639 | 2002 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 634 | 2018 |
| Prevention, diagnosis, therapy, and follow-up of lung cancer G Goeckenjan, H Sitter, M Thomas, D Branscheid, M Flentje, F Griesinger, ... Pneumologie 65 (01), 39-59, 2011 | 593* | 2011 |
| Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng, J He, Y Shi, ... JAMA oncology 4 (11), 1569-1575, 2018 | 515 | 2018 |
| Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer R Arriagada, A Dunant, JP Pignon, B Bergman, M Chabowski, ... Journal of clinical oncology 28 (1), 35-42, 2010 | 489 | 2010 |
| MDR1 gene expression and treatment outcome in acute myeloid leukemia R Pirker, J Wallner, K Geissler, W Linkesch, OA Haas, P Bettelheim, ... JNCI: Journal of the National Cancer Institute 83 (10), 708-712, 1991 | 474 | 1991 |
| Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial R Rosell, U Gatzemeier, DC Betticher, U Keppler, HN Macha, R Pirker, ... Annals of oncology 13 (10), 1539-1549, 2002 | 445 | 2002 |
| High D-dimer levels are associated with poor prognosis in cancer patients C Ay, D Dunkler, R Pirker, J Thaler, P Quehenberger, O Wagner, ... haematologica 97 (8), 1158, 2012 | 444 | 2012 |
| ERCC1 isoform expression and DNA repair in non–small-cell lung cancer L Friboulet, KA Olaussen, JP Pignon, FA Shepherd, MS Tsao, S Graziano, ... New England Journal of Medicine 368 (12), 1101-1110, 2013 | 431 | 2013 |
| Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung … FA Shepherd, C Domerg, P Hainaut, PA Jänne, JP Pignon, S Graziano, ... Journal of clinical oncology 31 (17), 2173-2181, 2013 | 367 | 2013 |
| Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ... Journal of Thoracic Oncology 5 (10), 1706-1713, 2010 | 358 | 2010 |
| Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell … R Rosell, G Robinet, A Szczesna, R Ramlau, M Constenla, BC Mennecier, ... Annals of oncology 19 (2), 362-369, 2008 | 344 | 2008 |
| Scientific advances in lung cancer 2015 AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ... Journal of Thoracic Oncology 11 (5), 613-638, 2016 | 339 | 2016 |
| EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases K Schmid, N Oehl, F Wrba, R Pirker, C Pirker, M Filipits Clinical Cancer Research 15 (14), 4554-4560, 2009 | 337 | 2009 |
